Kiora Q3 net loss $3.4M; cash $29M; advancing two Phase 2 retinal trials

KIORA PHARMACEUTICALS INC

2024-Q3 EPS reported $1.91 revenue$16,020,000

Cash and equivalents $29.0M at Sept 30, plus $1.8M collaboration receivables; runway into 2027.
Net loss $3.4M vs $5.8M in Q3 2023; decrease due to -$1.1M non-cash change in contingent consideration.
R&D expenses net $1.3M after $0.9M Théa reimbursement; G&A flat at $1.4M.
IND approved for ABACUS-2 Phase 2 study of KIO-301 in retinitis pigmentosa; first patient dosing in 2025.
Phase 2 KLARITY trial of KIO-104 designed; submission for approval on track for Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.